Cargando…

Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)

[Image: see text] N-Myristoyltransferase (NMT) is an essential eukaryotic enzyme and an attractive drug target in parasitic infections such as malaria. We have previously reported that 2-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-5-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole (34c) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rackham, Mark D., Brannigan, James A., Rangachari, Kaveri, Meister, Stephan, Wilkinson, Anthony J., Holder, Anthony A., Leatherbarrow, Robin J., Tate, Edward W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048319/
https://www.ncbi.nlm.nih.gov/pubmed/24641010
http://dx.doi.org/10.1021/jm500066b
_version_ 1782480522642980864
author Rackham, Mark D.
Brannigan, James A.
Rangachari, Kaveri
Meister, Stephan
Wilkinson, Anthony J.
Holder, Anthony A.
Leatherbarrow, Robin J.
Tate, Edward W.
author_facet Rackham, Mark D.
Brannigan, James A.
Rangachari, Kaveri
Meister, Stephan
Wilkinson, Anthony J.
Holder, Anthony A.
Leatherbarrow, Robin J.
Tate, Edward W.
author_sort Rackham, Mark D.
collection PubMed
description [Image: see text] N-Myristoyltransferase (NMT) is an essential eukaryotic enzyme and an attractive drug target in parasitic infections such as malaria. We have previously reported that 2-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-5-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole (34c) is a high affinity inhibitor of both Plasmodium falciparum and P. vivax NMT and displays activity in vivo against a rodent malaria model. Here we describe the discovery of 34c through optimization of a previously described series. Development, guided by targeting a ligand efficiency dependent lipophilicity (LELP) score of less than 10, yielded a 100-fold increase in enzyme affinity and a 100-fold drop in lipophilicity with the addition of only two heavy atoms. 34c was found to be equipotent on chloroquine-sensitive and -resistant cell lines and on both blood and liver stage forms of the parasite. These data further validate NMT as an exciting drug target in malaria and support 34c as an attractive tool for further optimization.
format Online
Article
Text
id pubmed-4048319
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-40483192014-06-09 Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP) Rackham, Mark D. Brannigan, James A. Rangachari, Kaveri Meister, Stephan Wilkinson, Anthony J. Holder, Anthony A. Leatherbarrow, Robin J. Tate, Edward W. J Med Chem [Image: see text] N-Myristoyltransferase (NMT) is an essential eukaryotic enzyme and an attractive drug target in parasitic infections such as malaria. We have previously reported that 2-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-5-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole (34c) is a high affinity inhibitor of both Plasmodium falciparum and P. vivax NMT and displays activity in vivo against a rodent malaria model. Here we describe the discovery of 34c through optimization of a previously described series. Development, guided by targeting a ligand efficiency dependent lipophilicity (LELP) score of less than 10, yielded a 100-fold increase in enzyme affinity and a 100-fold drop in lipophilicity with the addition of only two heavy atoms. 34c was found to be equipotent on chloroquine-sensitive and -resistant cell lines and on both blood and liver stage forms of the parasite. These data further validate NMT as an exciting drug target in malaria and support 34c as an attractive tool for further optimization. American Chemical Society 2014-03-05 2014-03-27 /pmc/articles/PMC4048319/ /pubmed/24641010 http://dx.doi.org/10.1021/jm500066b Text en Copyright © 2014 American Chemical Society Terms of Use CC-BY (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html)
spellingShingle Rackham, Mark D.
Brannigan, James A.
Rangachari, Kaveri
Meister, Stephan
Wilkinson, Anthony J.
Holder, Anthony A.
Leatherbarrow, Robin J.
Tate, Edward W.
Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)
title Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)
title_full Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)
title_fullStr Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)
title_full_unstemmed Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)
title_short Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)
title_sort design and synthesis of high affinity inhibitors of plasmodium falciparum and plasmodium vivax n-myristoyltransferases directed by ligand efficiency dependent lipophilicity (lelp)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048319/
https://www.ncbi.nlm.nih.gov/pubmed/24641010
http://dx.doi.org/10.1021/jm500066b
work_keys_str_mv AT rackhammarkd designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp
AT branniganjamesa designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp
AT rangacharikaveri designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp
AT meisterstephan designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp
AT wilkinsonanthonyj designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp
AT holderanthonya designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp
AT leatherbarrowrobinj designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp
AT tateedwardw designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp